MENLO PARK, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced that somavaratan data will be featured in an oral presentation and three posters during the 10th International Meeting of Pediatric Endocrinology (IMPE), to be held September 14-17, in Washington D.C. The abstracts are available on the IMPE 2017 website.
“IMPE brings together pediatric endocrine specialists from around the world every four years, and serves as a great opportunity to further highlight the depth of our long-term experience with somavaratan treatment in children with GHD,” said Colin Hislop, MD, Chief Development Officer. “We now have over 400 patients exposed to somavaratan, some of whom have been on our product for four years. We have built the largest data set of any long-acting growth hormone currently in development for pediatric patients, and are pleased with the results we have seen to date. With Phase 3 topline results expected around the end of September and plans to complete enrollment of our Phase 3 trial in Japan before year end, somavaratan is on a solid path to be the first to market for pediatric GHD among the new, long-acting growth hormone candidates in development.”
ORAL PRESENTATION (Growth and GH/IGF Axis #2 Free Communication Session)
Saturday, September 16, 2017 – 7:30 – 8:30 AM
FC58 - 3-Year Update of the Phase 2a and Long-term Safety Studies (VERTICAL and VISTA) of Somavaratan (VRS-317), a Long-acting rhGH for the Treatment of Pediatric Growth
POSTER PRESENTATION (Poster Session #1)
Thursday, September 14, 2017 – 5:45 – 6:45 PM
P1-820 - Dynamic Changes in IGF-I During Somavaratan Therapy in Pediatric Subjects with Growth Hormone Deficiency from the VISTA Long-Term Safety Study
POSTER PRESENTATION (Poster Session #2)
Friday September 15, 2017 – 11:30 AM – 12:30 PM
P2-824 - Change in Body Mass Index During Somavaratan Therapy in Pediatric Subjects with Growth Hormone Deficiency in the VISTA Long-Term Safety Study
LATE-BREAKING POSTER PRESENTATION (Poster Session #3)
Saturday, September 16, 2017 – 12:00 PM – 1:00 PM
P3-857 - Relative Changes in Bone Age and Linear Growth in Children With Growth Hormone Deficiency (GHD) Treated With Twice-Monthly Somavaratan (VRS-317)
About Versartis, Inc.
Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan, a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of GHD in children and adults. Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving adherence and, therefore, treatment outcomes.
For more information on Versartis, visit www.versartis.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, plans and timing of our clinical trials and the potential for eventual regulatory approval of somavaratan. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2016 and in our Quarterly Report on Form 10-Q for the three months ended June 30, 2017 which are on file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance, and our actual results may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release and we assume no obligation to update them after the date of this press release.
CONTACT: Contacts: Corporate Communications: Christine Labaree Corporate Affairs (650) 600-1697 firstname.lastname@example.org Investors: David Burke Director, Investor Relations (650) 516-2703 email@example.com